Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk's CEO reassures that side-effects are not an issue in the trial of CagriSema, their next-generation obesity drug. Despite weaker-than-expected trial results, the company is optimistic ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep. And regarding the slower-than-expected ...

Investors had dumped Novo shares in late December when data on a highly touted experimental Novo weight-loss shot called CagriSema fell far short of the expectations the company had set.

The amycretin data looks stronger than the 19% weight loss at 36 weeks generated for Lilly’s next-generation drug retatrutide in phase 2 (phase 3 data is expected in 2026) and 20.4% cagrisema ...

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep.